UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science

Acquisition builds on UCB's 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next generation disease-modifying therapies. Lead investigational asset, NRTX-1001, a neuronal cell therapy, is being evaluated in phase I/II clinical trials for...